Drug Profile
Research programme: needle-free injectable therapeutics - Glide/Paladin
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Glide Pharma
- Developer Glide Technologies
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in United Kingdom (SC, Needle-free injection)
- 28 Feb 2014 Endo Health Solutions and Paladin Labs combine to form Endo International
- 23 Mar 2011 Needle-free injectable formulations of sumatriptan, octreotide and fentanyl have entered clinical development